What is the upside for zymergen's stock?
Their forecasts range from $6.50 to $13.00. On average, they anticipate Zymergen's stock price to reach $9.33 in the next year. This suggests a possible upside of 198.2% from the stock's current price. View analysts' price targets for Zymergen or view top-rated stocks among Wall Street analysts.
What is zymergen's (Zym) price potential for the next year?
Their forecasts range from $6.50 to $13.00. On average, they anticipate Zymergen's stock price to reach $9.33 in the next year. This suggests a possible upside of 198.2% from the stock's current price.
Why are zymergen shares soaring today?
Rebounding from the 16% slide that they experienced last week, shares of Zymergen (NASDAQ: ZY) are soaring today as investors learn of an insider's significant acquisition of the company's stock.
When does zymergen report financial results for the third quarter?
EMERYVILLE, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Zymergen Inc. (Nasdaq: ZY) today announced it will report financial results for the third quarter 2021 after market close on Wednesday, November 3rd...
See more
Is Zymergen a good stock to buy?
Out of 7 analysts, 0 (0%) are recommending ZY as a Strong Buy, 0 (0%) are recommending ZY as a Buy, 4 (57.14%) are recommending ZY as a Hold, 2 (28.57%) are recommending ZY as a Sell, and 1 (14.29%) are recommending ZY as a Strong Sell.
Is Zymergen a public company?
Zymergen went public in April 2021, raising around $500 million in an IPO. The firm designs advanced materials technologies to improve manufacturing processes.
What happen to ZY stock?
Zymergen (ZY) Reports Q1 Loss, Tops Revenue Estimates Zymergen (ZY) delivered earnings and revenue surprises of 1.41% and 57.08%, respectively, for the quarter ended March 2022.
Will Zymergen stock go up?
Zymergen Inc (NASDAQ:ZY) The 3 analysts offering 12-month price forecasts for Zymergen Inc have a median target of 3.00, with a high estimate of 4.00 and a low estimate of 2.00. The median estimate represents a +48.51% increase from the last price of 2.02.
Is Zymergen going out of business?
Based on the latest financial disclosure, Zymergen has a Probability Of Bankruptcy of 69%. This is 55.62% higher than that of the Basic Materials sector and 65.11% higher than that of the Specialty Chemicals industry. The probability of bankruptcy for all United States stocks is 73.24% lower than that of the firm.
Should I sell Zymergen?
Should I buy or sell Zymergen stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zymergen in the last year. There are currently 3 sell ratings and 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Zymergen stock.
What went wrong at Zymergen?
However, Zymergen dropped a bomb in August when it ruled out any potential revenue in 2021 and 2022, citing technical issues with Hyaline among other things, and announced the abrupt exit of its then-CEO, Josh Hoffman.
Is Ginkgo Bioworks publicly traded?
Boston-based Ginkgo Bioworks began trading on the New York Stock Exchange on Friday, becoming the latest company to close a SPAC merger and go public. Shares opened at $11.15 apiece under ticker symbol “DNA,” giving the five-time CNBC Disruptor 50 company a market cap of nearly $2.5 billion.
How much money did Zymergen raise?
How much did Zymergen raise in IPO?
Zymergen Inc, backed by SoftBank Group Corp Inc's Vision Fund, is looking to raise around $100 million through an initial public offering in the United States, according to a regulatory filing on T...
When will Zymergen report financial results?
"I love the symbolism that we're going public on Earth Day," says Zymergen's Josh Hoffman. The synthetic biology company raised $500 million in an IPO set to value the company at more than $3 billion.
About Zymergen
EMERYVILLE, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Biofacturing leader Zymergen, today announced it will report financial results for the first quarter 2021 after market close on Monday, May 24th, 202...
2.8 Analyst's Opinion
Zymergen Inc. designs, engineers, and optimizes microbes for industrial applications in United States, Asia, and Europe.
Is Zymergen a buy right now?
Zymergen has received a consensus rating of Hold. The company's average rating score is 1.63, and is based on no buy ratings, 5 hold ratings, and 3 sell ratings.
When is Zymergen's next earnings date?
8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zymergen in the last year. There are currently 3 sell ratings and 5 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Zymergen stock.
What price target have analysts set for ZY?
Zymergen is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022. View our earnings forecast for Zymergen.
What is Joshua Hoffman's approval rating as Zymergen's CEO?
8 brokers have issued 12 month price objectives for Zymergen's stock. Their forecasts range from $6.50 to $13.00. On average, they anticipate Zymergen's share price to reach $9.33 in the next year.
Who are some of Zymergen's key competitors?
64 employees have rated Zymergen CEO Joshua Hoffman on Glassdoor.com. Joshua Hoffman has an approval rating of 62% among Zymergen's employees. This puts Joshua Hoffman in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 58.0% of employees surveyed would recommend working at Zymergen to a friend.
What is zymergen in manufacturing?
Some companies that are related to Zymergen include National Research (NRC), Science 37 (SNCE), Absci (ABSI), Inotiv (NOTV), Starpharma (SPHRY), Luna Innovations (LUNA), Auxly Cannabis Group (CBWTF), Bioqual (BIOQ), Inhibitor Therapeutics (INTI), HedgePath Pharmaceuticals (HPPI), ProMIS Neurosciences (ARFXF), AIkido Pharma (AIKI), AIkido Pharma (AIKI), Eloxx Pharmaceuticals (ELOX) and iSpecimen (ISPC). View all of ZY's competitors..
What is transparency in investing?
Zymergen Inc is a biofacturing company. Zymergen partners with nature to design, develop and manufacture bio-based breakthrough products that deliver value to customers in a broad range of industries. A unique combination of biology, chemistry, software and automation enables the company to design and create new materials.
Does Morningstar cover ratings?
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
What is zymergen in manufacturing?
Companies with ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Does market cap include convertible securities?
Zymergen Inc is a biofacturing company. Zymergen partners with nature to design, develop and manufacture bio-based breakthrough products that deliver value to customers in a broad range of industries. A unique combination of biology, chemistry, software and automation enables the company to design and create new materials.